Tina Tan's profile photo

Tina Tan

London, United Kingdom

Executive Editor at FirstWord HealthTech

Editor of @fwhealthtech | Geekoid that gets excited about techy stuff and strokes of engineering genius

Featured in: Favicon firstwordhealthtech.com Favicon wsj.com Favicon wiley.com Favicon informa.com (+2) Favicon aap.org Favicon contagionlive.com Favicon hcplive.com Favicon newsbreak.com Favicon mjhlifesciences.com Favicon komu.com

Articles

  • RX Review: RSV prevention and pediatric hospitalization

    1 week ago | contemporarypediatrics.com | Tina Tan |Albert Rizzo |Joanne Nazif

    Respiratory syncytial virus (RSV) is a leading cause of hospitalization in infants and young children, placing a significant burden on families, hospitals, and the healthcare system. Recent advancements in RSV prevention, including maternal vaccination and long-acting monoclonal antibodies, are beginning to shift the clinical conversation from reactive management to proactive protection.

  • RX Review: Expanding options and addressing gaps in RSV prevention

    1 week ago | contemporarypediatrics.com | Tina Tan |Albert Rizzo |Joanne Nazif

    As the field of RSV prevention continues to grow, pediatricians face both new opportunities and new challenges. From emerging immunoprophylaxis strategies to gaps in clinician and parent education, effective RSV management requires staying ahead of a changing landscape.

  • RX Review: Clesrovimab, RSV Education, and Immunization Uptake

    1 week ago | hcplive.com | Albert Rizzo |Tina Tan |Joanne Nazif

    CommentaryVideoJune 16, 2025Author(s):,Fact checked by:,In this video, part 2 in a 3-part series, panelists discuss clesrovimab's recent approval and gaps in clinician education. In this special report from HCP Live and Contemporary Pediatrics RX Review, Albert Rizzo, MD, moderates a discussion with Tina Tan, MD, and Joanne Nazif, MD, to address critical unmet needs and recent FDA approvals that are shaping pediatric respiratory syncytial virus (RSV) management.

  • Tina Tan, MD, comments on FDA expanded approval for MenQuadfi meningococcal disease vaccine

    1 month ago | contemporarypediatrics.com | Tina Tan

    Last week, the FDA approved an expanded indication for Sanofi's MenQuadfi meningococcal vaccine—for the prevention of invasive meningococcal disease (IMD) caused by Neisseria meningitidis serogroups A, C, W, and Y—that now includes children aged 6 weeks to 23 months. The approval expanded on the previous indication for individuals aged 2 years or older.

  • Tina Tan, MD, discusses impact of FDA's stricter COVID-19 vaccine policy for children

    1 month ago | contemporarypediatrics.com | Tina Tan

    On May 20, 2025, the FDA announced a new COVID-19 vaccination regulatory framework for future seasonal vaccines and additional clinical trial requirements for approval of vaccines intended for healthy individuals.

Contact details

Emails

[email protected]

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →

X (formerly Twitter)

Followers
3K
Tweets
8K
DMs Open
No
Tina Tan
Tina Tan @MedtechTinaTan
18 Oct 24

Here's some free advice to entrepreneurs doing their start-up pitch: Please do not mumble or worse, mumble quickly. Not naming names, just saying #startups #innovators #howtopitch

Tina Tan
Tina Tan @MedtechTinaTan
18 Oct 24

I don't think this is said enough nor do #healthtech developers take this into account but as .@dacadoo CEO says about getting consumers to adopt your #digitalhealth product: make it relevant, make it easy to understand, make it fun #consumerhealth #FH24 https://t.co/DFXWQBKtbT

Tina Tan
Tina Tan @MedtechTinaTan
18 Oct 24

CEOs of #digitaldrug combination products highlight how adding the software-enhanced label to a drug could benefit pharma by strengthening patent estate, making that patent cliff less steep #FH24 #healthtech #digitaltherapeutics .@closed_loop_med .@Click_Tx https://t.co/HbkCIOKTGp